Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report

BACKGROUND: Lung cancer remains the leading cause of cancer-related mortality. Studies have revealed that a combination of crizotinib and EGFR tyrosine kinase inhibitors (TKIs) could be an effective treatment option for patients with sensitizing EGFR mutations and de novo or acquired MET amplificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhicong, Song, Pengtao, Zhou, Lingyan, Ji, Dongxiang, Shen, Hui, Dong, Hui, Feng, Xueren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350420/
https://www.ncbi.nlm.nih.gov/pubmed/37465082
http://dx.doi.org/10.2147/CMAR.S412199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350420/
https://www.ncbi.nlm.nih.gov/pubmed/37465082
http://dx.doi.org/10.2147/CMAR.S412199

Ejemplares similares